Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Slides:

Advertisements

Similar presentations

Independent variables (baseline) Loge (HOMA-IR) b P

Advertisements

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Blood glucose, insulin and C-peptide concentrations (A), insulin dose received and BGC (B) for one neonate treated with insulin over 24 hours. Blood glucose,

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

(A) Plasma renin activity in Wistar rats, SHRs, and DOCA-salt rats, n = 8 to 9/group; data are presented as mean ± S.E.M. Dose-response relationship on.

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

Glucose, insulin, and AGE levels during an OGC before and after RT

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Effect of the acute administration of benzylamine plus vanadate on oral glucose tolerance test in STZ-induced diabetic rats. Effect of the acute administration.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Appearance of insulin in plasma and CSF at different times after the administration of subcutaneous DET and GLAR in mice and the effect of chronic DET.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

TXNIP and caspase-1 protein levels are increased in the adipose tissue of ob/ob mice. TXNIP and caspase-1 protein levels are increased in the adipose tissue.

Measurement of insulin release from islets evoked by glucose, diazoxide, and high K+. Measurement of insulin release from islets evoked by glucose, diazoxide,

Glucose tolerance in WT and TRPM2-KO mice.

The underlying physiological basis of the HOMA model.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

The portal-arterial (P-A) insulin gradient and arterial plasma c-peptide levels in the control period (−40 to 0 min) and after administration of the glycogen.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

USP2–45 regulates hepatic gluconeogenesis.

Intracerebroventricular (ICV) insulin infusion increases TG secretion.

Sympathetic denervation decreases VLDL-TG secretion in the fasted state. Sympathetic denervation decreases VLDL-TG secretion in the fasted state. A: Plasma.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

Glucose stimulates GLP-1 secretion from the perfused rat intestine by a dose- and absorption-dependent manner. Glucose stimulates GLP-1 secretion from.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Effect of cold exposure on determinants of glucose tolerance.

A: Comparison of the glucose-dependent insulinotropic effects of efaroxan and phentolamine. A: Comparison of the glucose-dependent insulinotropic effects.

HFD feeding induced insulin resistance in TRIB3 MOE mice.

High-glucose–induced insulin resistance in TRIB3 MOE mice.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Treatment of high-fat diet–fed mice with TTR-ASOs decreases circulating TTR and RBP4 levels, and improves insulin sensitivity. Treatment of high-fat diet–fed.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Metabolic effects of VSG in GLP-1r KO mice.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Estimated glucose delta values (mmol/L) after glucagon injection (5 µg/kg) in octreotide-treated rats. Estimated glucose delta values (mmol/L) after glucagon.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

A loading dose decreases the time to achieve the target concentration.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Initiation and adjustment of insulin regimens.

Postoperative blood glucose levels and total insulin requirement.

Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Presentation transcript:

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different doses in rats. Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different doses in rats. Intraperitoneal NPH insulin and DET produced similar levels as a function of dose in plasma (A and D). Likewise, there were dose-dependent increases of CSF insulin with both NPH insulin and DET, with apparent saturation of the CSF insulin levels occurring by the 3 units/kg dose (B and E). Plasma glucose decreased in a dose-dependent manner after intraperitoneal NPH insulin or DET (C and F). Significant differences are described in the text. Denovan P. Begg et al. Diabetes 2015;64:2457-2466 ©2015 by American Diabetes Association